SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc., the personalized medicine company dedicated to improving the diagnosis and treatment of patients with rheumatoid arthritis (RA), lupus and other autoimmune diseases, announced today a collaboration with Leiden University Medical Center (LUMC) to assess the epigenetic signatures of patients with early synovitis and rheumatoid arthritis. “With the signing of this collaboration with LUMC, Ignyta now has a global reach to study patients with undifferentiated arthritis and rheumatoid arthritis, taking us another step closer to achieving our goal of developing a diagnostic assay for patients with early RA,” said Jonathan Lim, M.D., co-founder, chairman and CEO of Ignyta. “LUMC is one of the world’s leading institutions in researching and treating patient with arthritis, and we are pleased to be collaborating with them in this important area of research.”
